Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 10;13:808041. doi: 10.3389/fgene.2022.808041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Han, Fang, Wang, Zhang and Xue.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

TGFβ2 and immunotherapy and chemotherapy. Differences in immune checkpoints between high and low TGFβ2 groups, PD-1 (A), PD-L1 (B) and CTLA-4 (C). (D) Heatmap visualized the response to anti-CTLA4 and anti-PD1 therapies between the two groups. (E) The histogram showed the responsiveness of immunotherapy between high and low TGFβ2 groups, the height of each bar represents the frequency of change. (F) Boxplots depicted the differences in the estimated IC50 levels of Lapatinib, Metformin, Methotrexate, Mitomycin. C, Paclitaxel, Cisplatin, AZD6244, BIBW2992, Sorafenib and Erlotinib between the high and low TGFβ2 groups.